LG Chem initiates clinical development of drugs for treatment of arthritis
상태바
LG Chem initiates clinical development of drugs for treatment of arthritis
  • Kevin Lee 기자
  • 승인 2021.11.06 07:00
  • 댓글 0
이 기사를 공유합니다

Plans to evaluate the safety through clinical trials on patients with knee osteoarthritis

LG Chem announced on Nov. 4 that it has received approval from the Korean Ministry of Food and Drug Safety for the Phase 1b/2 clinical trials based on the positive pre-clinical results of LG00034053, a new drug candidate for treatment of osteoarthritis.

LG Chem plans to accelerate the development of new drugs by designing clinical trials which links Phases 1 and 2.

LG Chem plans to accelerate the development of new drugs by designing clinical trials.
LG Chem plans to accelerate the development of new drugs by designing clinical trials.

Through this approval, LG Chem will conduct research at Samsung Medical Center to evaluate indicators such as safety and tolerability, pharmacokinetics, and effectiveness in patients with mild and moderate knee osteoarthritis, to select the most optimal dose.

President Son Jee-wong of the Life Sciences Co., stated “For all the arthritis patients around the world who still suffer from limited treatment options, we will develop a new drug that not only relieves the pain but also prevents the progression and the cause of the disease.”


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.
주요기사